Protein-tyrosine kinase inhibitor

Known as: Tyrosine Kinase Inhibitor, TK Inhibitors, Protein Tyrosine Kinase Inhibitors 
Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals… (More)

Topic mentions per year

Topic mentions per year

1958-2017
050019582017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
Using MRI techniques, we show here that normalization of tumor vessels in recurrent glioblastoma patients by daily administration… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2003
Highly Cited
2003
One challenging aspect in the clinical development of molecularly targeted therapies, which represent a new and promising… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2003
Highly Cited
2003
CONTEXT More persons in the United States die from non-small cell lung cancer (NSCLC) than from breast, colorectal, and prostate… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Through sequencing analysis of blood or bone marrow samples from patients with chronic myeloid leukemia, we identified BCR-ABL… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2001
Highly Cited
2001
BACKGROUND BCR-ABL, a constitutively activated tyrosine kinase, is the product of the Philadelphia chromosome. This enzyme is… (More)
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2000
Highly Cited
2000
STI571 (formerly known as CGP 57148B) is a protein-tyrosine kinase inhibitor that is currently in clinical trials for the… (More)
  • figure 1
  • figure 4
  • figure 2
  • figure 3
  • figure 5
Is this relevant?
Highly Cited
2000
Highly Cited
2000
STI 571 (formerly known as CGP 57148B) is a known inhibitor of the c-abl, bcr-abl, and platelet-derived growth-factor receptor… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 6
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Targeting the tyrosine kinase activity of Bcr-Abl with STI571 is an attractive therapeutic strategy in chronic myelogenous… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
1997
Highly Cited
1997
The Philadelphia chromosome found in virtually all cases of chronic myeloid leukemia (CML) and in about one third of the cases of… (More)
  • figure 2
  • figure 1
  • table 2
  • table 1
  • figure 4
Is this relevant?
Highly Cited
1996
Highly Cited
1996
Here, we have studied the activity of a novel protein-tyrosine kinase inhibitor that is selective for the Src family of tyrosine… (More)
Is this relevant?